94426-72-9

Usage

Uses

Used in Pharmaceutical Industry:
Oxirane, 2-[2-(phenylmethoxy)ethyl]is used as a key intermediate in the synthesis of pharmaceuticals for its ability to form various biologically active compounds. Its reactivity and stability, along with its compatibility in organic solvents, make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
Oxirane, 2-[2-(phenylmethoxy)ethyl]is utilized as a building block in the creation of agrochemicals, contributing to the development of effective and stable products for agricultural applications. Its versatility in chemical transformations allows for the synthesis of a wide range of agrochemicals.
Used in Organic Synthesis:
Oxirane, 2-[2-(phenylmethoxy)ethyl]is employed as a versatile reactant in organic synthesis, taking advantage of its epoxy group and ring-opening reactions to form a variety of complex organic molecules. This makes it an important compound in the field of chemical research and development.

Upstream product

• 627-27-0 homoalylic alcohol 
• 70388-33-9 4-benzyloxybut-1-ene 
• 71998-69-1 (+/-)-4-benzyloxy-butane-1,2-diol 
• 100-39-0 benzyl bromide 
• 19098-31-8 3,4-epoxy-1-butanol 
• 588-67-0 benzyl 1-butyl ether 
• 100-44-7 benzyl chloride 
• 94426-71-8 (+/-)-4-(2-benzyloxyethyl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 110652-77-2 1-Benzyloxy-7-trimethylsilanyl-hept-5-yn-3-ol 
• 103025-10-1 1,4-Bis-benzyloxy-butan-2-ol 
• 94426-76-3 1-<4-(benzyloxy)-2-hydroxybutyl>thymine 
• 217650-20-9 (R)-1,7-Bis-benzyloxy-octan-3-ol 
• 223906-11-4 6-benzyloxy-4-hydroxy-1-trimethylsilyl-1-hexyne 
• 170798-94-4 1-(benzyloxy)octan-3-ol 
• 71998-69-1 (S)-4-benzyloxy-1,2-butanediol 
• 115114-87-9 (2R)-2-(2-benzyloxyethyl)oxirane 
• 85960-55-0 (S)-(2-phenylmethoxyethyl)oxirane 
• 69985-32-6 (R)-4-phenylmethoxy-1,2-butanediol 
• 934193-47-2 1-benzyloxy-hept-5-yn-3-ol 

Relevant academic research and scientific papers

IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST

Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

GINGEROL DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST BIOFILM FORMATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING BIOFILM-CAUSED INFECTION SYMPTOM

The present invention relates to a gingerol derivative having inhibitory activity against biofilm formation and a pharmaceutical composition for preventing or treating infections caused by biofilms including the gingerol derivative as an active ingredient. The gingerol derivative of the present invention exhibits significantly improved binding affinity for LasR and inhibitory activity against biofilm formation. Therefore, the gingerol derivative of the present invention can act on various membrane surfaces where biofilms tend to form and can effectively inhibit the formation of the corresponding biofilms. In addition, the use of the pharmaceutical composition according to the present invention can fundamentally prevent or treat a variety of infections caused by biofilms due to the presence of the gingerol derivative in the pharmaceutical composition.

Site-Selective Conversion of Azido Groups at Carbonyl α-Positions to Diazo Groups in Diazido and Triazido Compounds

This paper reports on the selective conversion of alkyl azido groups at the carbonyl α-position to diazo compounds. Through β-elimination of dinitrogen, followed by hydrazone formation/decomposition, α-azidocarbonyl moieties were transformed into α-diazo carbonyl groups in one step. As these reaction conditions do not involve aryl or general alkyl azides, site-selective conversions of di- and triazides were achieved. Through this method, the successive site-selective conjugation of the triazido molecule with three different components is demonstrated.

A convenient synthesis of the enantiomerically pure (S)-2,4-dihydroxybutyl-4-hydroxybenzoate using hydrolytic kinetic resolution

(S)-2,4-Dihydroxybutyl-4-hydroxybenzoate was prepared in an extremely simple and practical way with high enantiomeric excess (99% ee) using Jacobsen’s Hydrolytic Kinetic Resolution technique as a key step and source of chirality.

Structure-Activity Relationships of 6- and 8-Gingerol Analogs as Anti-Biofilm Agents

Pseudomonas aeruginosa is a causative agent of chronic infections in immunocompromised patients. Disruption of quorum sensing circuits is an attractive strategy for treating diseases associated with P. aeruginosa infection. In this study, we designed and synthesized a series of gingerol analogs targeting LasR, a master regulator of quorum sensing networks in P. aeruginosa. Structure-activity relationship studies showed that a hydrogen-bonding interaction in the head section, stereochemistry and rotational rigidity in the middle section, and optimal alkyl chain length in the tail section are important factors for the enhancement of LasR-binding affinity and for the inhibition of biofilm formation. The most potent compound 41, an analog of (R)-8-gingerol with restricted rotation, showed stronger LasR-binding affinity and inhibition of biofilm formation than the known LasR antagonist (S)-6-gingerol. This new LasR antagonist can be used as an early lead compound for the development of anti-biofilm agents to treat P. aeruginosa infections.

SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

Novel pyrrolopyridine derivatives and its use as HIV inhibitor

The present invention relates to a pyrrolopyridine derivative expressed as chemical formula 1, specifically a compound including a substituent group having an oxatane group in R1, its stereoisomer or racemic body, their pharmaceutically acceptable salts or their solvate, a manufacturing method thereof, and an antivirus composition containing the same as an active ingredient, wherein the compound expressed as chemical formula 1 has excellent selectivity and physiological activity with respect to wild type or resistant HIV-1 and therefore can be used as a remedy for AIDS.

4-Isopropylchroman-3-ol derivatives

The present invention relates to a novel 4-isopropylchroman-3-ol compound, a pharmaceutical composition comprising the novel compound as an effective component, and to an intermediate compound useful for synthesizing the compound. When administered to a patient with a drug causing toxicity, the novel 4-isopropylchroman-3-ol compound exhibits efficacy of reducing toxicity of the drug by reducing antagonism regarding a T-type calcium channel and/or activity of cytochrome P450 isozyme.

A concise stereoselective total synthesis of diplodialide C

An asymmetric total synthesis of diplodialide C has been achieved starting from commercially available homoallylic alcohol. Regioselective opening of the chiral epoxide, cross-metathesis reaction, and Yamaguchi macrolactonization were used as the key step

First stereoselective total synthesis of Neocosmosin A: A facile approach

First stereoselective concise synthesis of Neocosmosin A, with in vitro binding affinity for human opioid and cannabinoid receptors, has been reported using readily available starting materials such as methylacetoacetate, cyclohexanone, and homoallyl alco